Query Result Set
Skip Navigation Links
   ActiveUsers:1448Hits:19735058Skip Navigation Links
Show My Basket
Contact Us
IDSA Web Site
Ask Us
Today's News
HelpExpand Help
Advanced search

  Hide Options
Sort Order Items / Page
VACCINATION (4) answer(s).
 
SrlItem
1
ID:   126005


Cost effectiveness comparison of response strategies to a large: impact of timing and surge capacity / Kyriacou, Demetrios N; Dobrez, Debra; Parada, Jorge P; Steinberg, Justin M   Journal Article
Kyriacou, Demetrios N Journal Article
0 Rating(s) & 0 Review(s)
Publication 2012.
Summary/Abstract Rapid public health response to a large-scale anthrax attack would reduce overall morbidity and mortality. However there is uncertainty about the optimal cost effective response strategy based on timing of intervention, public health, resources, and critical care facilities. We connected a decision analytic study to compare response strategies to a theoretical large scale anthrax attack on the Chicago metropolitan area beginning either Day 2 or Day 5 after the attack. These strategies correspond to the policy option set forth by the Anthrax Modeling Working Group for population-wide response to a large scale anthrax attack: (1) postattack antibiotic prophylaxix, (2) postattack antibiotic prophylaxis and vaccination, (3) Preattack vaccination with postattack antibiotic prophylaxis, and (4) preattack vaccination with postattack antibiotic prophylaxis and vaccination.
        Export Export
2
ID:   105110


Does of reason / Yousfzai, Ashfaq   Journal Article
Yousfzai, Ashfaq Journal Article
0 Rating(s) & 0 Review(s)
Publication 2011.
Key Words Health  Taliban  Children  Vaccination  Polio  Pakistan - 1967-1977 
        Export Export
3
ID:   183860


Economic Case for Waiving Intellectual Property Rights on Covid Vaccines / Roy, Gopal Krishna   Journal Article
Roy, Gopal Krishna Journal Article
0 Rating(s) & 0 Review(s)
Summary/Abstract India and South Africa approached the World Trade Organisation to negotiate the temporary waiver of Intellectual Property (IP) rights on Covid-19 vaccines to remove the artificial barrier of patents and boost vaccine production. This commentary advocates for the waiver of IP rights on Covid-19 vaccines. First, the article makes a case for the debate on the validity of the Covid-19 vaccine to qualify for a patent. Market failure and underinvestment in research and development arguments do not hold for granting a patent to Covid vaccines. Next, the article briefly reviews the evidence on the association between vaccination and virus mutations. Evidence suggests that waiving patents is vital to increase vaccination worldwide and curb mutation and reduce the risk of more infectious new variants. Finally, the article argues that the rationale for a patent is economical, based on incentivising innovation and therefore, the losses suffered by various sectors of the economy due to new variant induced fatalities and lockdowns need to be considered for a case for its waiver.
        Export Export
4
ID:   181352


Role of who in the first year of the fight against covid-19 / Akimov, A   Journal Article
Akimov, A Journal Article
0 Rating(s) & 0 Review(s)
Summary/Abstract THE COVID-19 pandemic, which began as just another routine outbreak of infection in a region where many other virus infections are endemic (for example, influenza), became in a matter of months a global medical challenge to states and international institutions and a threat in many other respects [2].
        Export Export